Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
Part of paid clinical trials in Rochester, Minnesota.
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Study ID
- NCT04564989
- Status
- Recruiting
Conditions
- Carcinoma, Squamous Cell
- Head and Neck Squamous Cell Carcinoma
- Oropharyngeal Squamous Cell Carcinoma
- Oropharynx Squamous Cell Carcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
The primary goal of this study is to examine whether recurrence of HPV-associated OPSCC can be predicted by two factors: 1) mutations in genes called TRAF3 and CYLD, and 2) measurements of circulating HPV DNA in blood plasma. The study will also investigate whether HPV integration is associated with TRAF3 and CYLD mutations, and whether recurrence prediction improves when looking at HPV integration along with TRAF3 and CYLD mutations.
Key Dates
- Start date
- Nov 19, 2020
- Status verified
- Apr 2026
- Primary completion
- Nov 30, 2033
- Completion
- Nov 30, 2033
Study Design
- Enrollment
- 220 participants (estimated)
Arms
- Arm: HPV+ OPSCC PatientsPatients with p16+ squamous cell carcinoma of the oropharynx (or unknown primary) who will receive definitive cancer treatment.
Primary Outcome Measure
Recurrence of OPSCC [ Time Frame: From date of therapy completion until biopsy-proven recurrence, assessed up to 5 years ]
Central Contacts
- Lori Stravers919-966-4432
- Wendell Yarbrough, MD919-843-7091
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic | Rochester | Minnesota | 55905 | - |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | Wendell Yarbrough, MD (PRINCIPAL_INVESTIGATOR) |
| Trident Medical Center (HCA Healthcare ) | North Charleston | South Carolina | 29406 | David Neskey, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Rochester, MN
By condition
Related Studies
- Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone SurgeryPHASE2 · Recruiting · ECOG-ACRIN Cancer Research Group · Birmingham, Alabama
- Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell CarcinomaRecruiting · UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina
- Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer PatientsPHASE2 · Recruiting · Vyriad, Inc. · Phoenix, Arizona
- Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell CancerPHASE2 · Recruiting · Wake Forest University Health Sciences · Winston-Salem, North Carolina